AbbVie Reports meta-analysis Data for Pembrolizumab in ALS

AbbVie today announced meta-analysis results for pembrolizumab in patients with ALS. The study demonstrated that pembrolizumab improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of ALS and support the continued development of pembrolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.